Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 25Terminated 4Unknown 3Withdrawn 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 7CNS 4Sarcoma 2Other hematologic neoplasm 2Dermatologic 1Breast 1

Conditions

Gliosarcoma 2Glioblastoma 2Central Nervous System Neoplasms 2

Interventions

Cyclophosphamide 9Radiotherapy 8Temozolomide 6Magnetic Resonance Spectroscopy 6Filgrastim 6Doxorubicin 6pazopanib 5Gemcitabine 5pembrolizumab 4Vincristine 4Radiation 4Etoposide 4Docetaxel 4Carboplatin 4Biopsy 4Trabectedin 3Taxes 3Specimen Handling 3Paclitaxel 3Nivolumab 3Irinotecan 3Drug Therapy 3olaparib 2niraparib 2liposomal doxorubicin 2fludarabine phosphate 2fludarabine 2brigimadlin 2Trastuzumab 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Carmustine × Sarcoma × Clear all
NCT00814593 2019-05-10

Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery

Lisata Therapeutics, Inc.

Phase 2 Withdrawn
CNSSarcoma

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00046878 2013-03-28

Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Duke University

Phase 2 Withdrawn
CNSSarcoma

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡